ACAD
38.17
+0.26
+0.69%
AEMD
7.05
-0.1
-1.40%
APRI
1.35
+0.12
+9.76%
ARNA
2.71
+0.06
+2.26%
ATEC
0.54
-0.03
-5.26%
CNAT
4.05
+0.37
+10.05%
CRXM
0.37
-0.02
-5.13%
CYTX
0.315
+0.016
+5.246%
DXCM
94.19
+0.45
+0.48%
GNMK
10.02
+0.59
+6.26%
HALO
18.41
+0.37
+2.05%
ILMN
201.7
-0.24
-0.12%
INNV
0.148
+0.003
+2.069%
INO
7.73
+0.75
+10.74%
ISCO
3.98
+0.33
+9.04%
ISIS
51.54
-0.02
-0.04%
LGND
95.04
+0.79
+0.84%
LPTN
0.225
+0.015
+7.092%
MBVX
1.685
-0.005
-0.296%
MEIP
1.73
+0.04
+2.37%
MNOV
2.94
-0.03
-1.01%
MRTX
26.66
+1.17
+4.59%
MSTX
0.47
+0.02
+3.96%
NBIX
46.67
+0.41
+0.89%
NUVA
53.75
+1
+1.90%
ONCS
5.2
+0.02
+0.48%
ONVO
2.54
+0.04
+1.60%
OREX
2.89
+0.13
+4.71%
OTIC
23.5
+0.12
+0.51%
QDEL
20.45
-0.25
-1.21%
RCPT
231.96
0.00
0.00%
RGLS
8.27
+0.79
+10.56%
RMD
52.47
+0.82
+1.59%
SCIE
0.015
+0.001
+3.5714%
SPHS
0.89
+0.03
+3.49%
SRNE
13.65
+0.33
+2.48%
TROV
6.33
+0.55
+9.52%
VICL
0.59
+0.03
+5.32%
VOLC
18
0.00
0.00%
ZGNX
18.41
+1.35
+7.91%
ACAD
38.17
+0.26
+0.69%
AEMD
7.05
-0.1
-1.40%
APRI
1.35
+0.12
+9.76%
ARNA
2.71
+0.06
+2.26%
ATEC
0.54
-0.03
-5.26%
CNAT
4.05
+0.37
+10.05%
CRXM
0.37
-0.02
-5.13%
CYTX
0.315
+0.016
+5.246%
DXCM
94.19
+0.45
+0.48%
GNMK
10.02
+0.59
+6.26%
HALO
18.41
+0.37
+2.05%
ILMN
201.7
-0.24
-0.12%
INNV
0.148
+0.003
+2.069%
INO
7.73
+0.75
+10.74%
ISCO
3.98
+0.33
+9.04%
ISIS
51.54
-0.02
-0.04%
LGND
95.04
+0.79
+0.84%
LPTN
0.225
+0.015
+7.092%
MBVX
1.685
-0.005
-0.296%
MEIP
1.73
+0.04
+2.37%
MNOV
2.94
-0.03
-1.01%
MRTX
26.66
+1.17
+4.59%
MSTX
0.47
+0.02
+3.96%
NBIX
46.67
+0.41
+0.89%
NUVA
53.75
+1
+1.90%
ONCS
5.2
+0.02
+0.48%
ONVO
2.54
+0.04
+1.60%
OREX
2.89
+0.13
+4.71%
OTIC
23.5
+0.12
+0.51%
QDEL
20.45
-0.25
-1.21%
RCPT
231.96
0.00
0.00%
RGLS
8.27
+0.79
+10.56%
RMD
52.47
+0.82
+1.59%
SCIE
0.015
+0.001
+3.5714%
SPHS
0.89
+0.03
+3.49%
SRNE
13.65
+0.33
+2.48%
TROV
6.33
+0.55
+9.52%
VICL
0.59
+0.03
+5.32%
VOLC
18
0.00
0.00%
ZGNX
18.41
+1.35
+7.91%
Home » Bio: Joseph E. Payne

Bio: Joseph E. Payne

Joseph E. Payne brings with him an exceptional track record of ushering novel therapeutics to the clinic including successful experience developing sophisticated targeted RNAi nanoparticle technologies.  Joseph’s background includes over 20 years of successful drug discovery experience at Merck Research Labs, DuPont Pharmaceuticals, Bristol-Myers Squibb, Kalypsys, and Nitto Denko as evidenced by over 40 publications and patents, and 7 FDA-approved IND clinical candidates.  His academic training includes BYU (magna cum laude, Chemistry and Physics), University of Calgary (Synthetic Organic Chemistry), and MIT Sloan School of Management (Executive Training, Supply Chain and Logistics.